Skip to main content
. Author manuscript; available in PMC: 2025 Feb 1.
Published in final edited form as: Eur Urol Oncol. 2023 Jul 11;7(1):83–90. doi: 10.1016/j.euo.2023.05.013

Table 2 –

Summary of worst adverse event per patient

Relationship to treatment Adverse event Grade RT +
paclitaxel +
trastuzumab (n
= 20), n (%)
RT +
paclitaxel (n =
45), n (%)
Definitely, probably, or possibly Worst nonhematological 1 4 (20.0) 10 (22.2%)
2 4 (20.0) 9 (20.0%)
3 8 (40.0) 7 (15.6%)
4 1 (5.0) 1 (2.2%)
5 1 (5.0) 0 (0%)
Worst overall 1 0 (0.0) 4 (8.9%)
2 4 (20.0) 15 (33.3%)
3 15 (75.0) 22 (48.9%)
4 0 (0.0) 4 (8.9%)
5 1 (5.0) 0 (0.0%)
Any a Worst nonhematological 1 5 (25.0) 10 (22.2%)
2 4 (20.0) 11 (24.4%)
3 9 (45.0) 10 (22.2%)
4 1 (5.0) 1 (2.2%)
5 1 (5.0) 0 (0%)
Worst overall 1 0 (0.0) 2 (4.4%)
2 4 (20.0) 9 (20.0%)
3 15 (75.0) 26 (57.8%)
4 0 (0.0) 6 (13.3%)
5 1 (5.0) 2 (4.4%)

CTCAE = Common Terminology Criteria for Adverse Events; RT = radiotherapy.

a

Includes adverse events where relationship to protocol treatment is missing. Adverse events were graded with CTCAE version 3.0.